Page 2 - சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் Today - Breaking & Trending Today

SUO 2020: New Paradigms in NMIBC: The Evolving Role of Checkpoint Inhibition

SUO 2020: New Paradigms in NMIBC: The Evolving Role of Checkpoint Inhibition
(UroToday.com) The Society of Urologic Oncology (SUO) 2020 virtual meeting featured a session examining the new and emerging agents in bladder cancer chaired by Dr. Neal Shore, which included a presentation by Dr. Ashish Kamat discussing the evolving role of checkpoint inhibition in nonmuscle-invasive bladder cancer (NMIBC).
Dr. Kamat notes that Bacillus Calmette Guerin (BCG) is the original cancer immunotherapy with urologists administering approximately 1.2 million doses of BCG for bladder cancer. However, there are BCG failures, with ~30% failing at 1 year, and ~40% failing at 2-3 years after induction therapy. Classification of BCG failure is as follows: ....

United States , Myrtle Beach , South Carolina , Zachary Klaassen , Aashish Kamat , Calmette Guerin , Society Of Urologic Oncology Annual Meeting , Society Of Urologic Oncology , Augusta University Medical College Of Georgia , Md Anderson Cancer Center , Cancer Research , Georgia Cancer Center , Wayneb Duddleston Professor Of Cancer Research , Urologic Oncology , Neal Shore , Bacillus Calmette Guerin , Lancet Oncology , Vista Trial , Atezolizumab Plus One Year , Medical Director , Atlantic Urologic Clinics , Cancer Center , Assistant Professor , Medical College , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் ,

SUO 2020: Next Generation Clinical Trial Design BCG-Unresponsive NMIBC

SUO 2020: Next Generation Clinical Trial Design BCG-Unresponsive NMIBC
(UroToday.com) There have been several recent single-arm trials in the Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) setting (Table 1).
The first question that arises is whether these single-arm trials are enough or do we need to randomize patients for our future trials. As seen in Table 1, these treatments are given for a minimum of two years, requiring a high number of physician visits during these treatment years. To get more accurate information, we may need to consider randomizing these patients in the long run and compare these treatments head to head before making any informed decisions. ....

United States , Hanan Goldberg , Max Kates , Bladder Cancer Program Assistant Professor Of Urology , Brady Urological Institute , Department Of Urology , Society Of Urologic Oncology Annual Meeting , Urology Department , Drug Administration , Bacillus Calmette Guerin , Federal Drug Administration , Bladder Cancer Program Assistant Professor , Johns Hopkins , Assistant Professor , Medical University , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , ஹனன் கோல்ட்பர்க் , அதிகபட்சம் கேட்ஸ் , சிறுநீர்ப்பை புற்றுநோய் ப்ரோக்ர்யாம் உதவியாளர் ப்ரொஃபெஸர் ஆஃப் சிறுநீரகம் , பிராடி சிறுநீரக நிறுவனம் , துறை ஆஃப் சிறுநீரகம் , சமூகம் ஆஃப் சிறுநீரக புற்றுநோயியல் ஆண்டு சந்தித்தல் , சிறுநீரகம் துறை , சிறுநீர்ப்பை புற்றுநோய் ப்ரோக்ர்யாம் உதவியாளர் ப்ரொஃபெஸர் , ஜான்ஸ் ஹாப்கின்ஸ் ,